

Supplementary data 1 depicts the PRISMA checklist for systematic reviews

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Submitted PROSPERO
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	N/A
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	N/A
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	N/A

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	N/A
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	5
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	5
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	N/A
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	6
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	6
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A

Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	None

Supplementary data 2: Summary of the geographical distribution of the 829 intervention-based studies

Country	Number of studies	Country	Number of studies
China	291	Ecuador	1
USA	188	Ice Land	1
France	63	Iraq	1
Spain	28	Jordan	1
Canada	20	New Zealand	1
Iran	18	Philippines	1
Egypt	17	Poland	1
United Kingdom	17	Poland	1
Italy	16	Qatar	1
Brazil	14	Singapore	1
Germany	14	South Africa	1
Mexico	11	Thailand	1
Netherlands	10	Vietnam	1
Greece	8	n	829
Multicenter	13		
India	7		
Australia	6		
Denmark	6		
Pakistan	6		
Switzerland	6		
Turkey	6		
Belgium	5		
Austria	4		
Colombia	4		
Norway	4		
Argentina	3		
Honk Kong	3		
Ireland	3		
Israel	3		
Korea	3		
Tunisia	3		
Guinea	2		
Hungary	2		
Japan	2		
Russia	2		
Slovenia	2		
Sweden	2		
Bosnia	1		
Czech Republic	1		
Caribbean	1		
Chile	1		

Supplementary data 3: Summarizes the ongoing clinical trials that are assessing various vaccine trials

Study identification number	Country	Sample size	Vaccine type
NCT04313127	China	108	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
NCT04299724	China	100	Pathogen-specific aAPC
NCT04276896	China	100	Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs
ChiCTR2000030750	China	120	COVID-19 epitope DC vaccine
NCT04327206	Australia	4170	BCG Vaccine
NCT04334980	Canada	84	Bac TRL-Spike
NCT04328441	Netherlands	1500	BCG Vaccine
EUCTR2020-000919-69-NL	France	1000	BCG vaccine
NCT04350931	Egypt	900	BCG Vaccine
NCT04357028	Egypt	200	Measles-Mumps-Rubella Vaccine
NCT04369794	Brazil	1000	BCG vaccine
NCT04368728	USA	7600	BNT162a1; BNT162b1; BNT162b2; BNT162c2
NCT04373291	Guinea	1500	BCG vaccine
NCT04283461	USA	105	mRNA-1273
NCT04362124	Colombia	1000	BCG vaccine
NCT04324606	UK	1090	ChAdOx1 nCoV-19
NCT04336410	USA	40	INO-4800
NCT04368988	Australia	131	Matrix-M Adjuvant
ChiCTR2000030906	China	108	Recombinant novel coronavirus vaccine (adenoviral vector)

Supplementary data 4: Summarizes the ongoing clinical trials that are assessing herbal medicines in various trials

Registry number	Country	Herbal interventions
ChiCTR2000030522	China	Ma-Xing-Gan-Shi decoction
ChiCTR2000030479	China	Yi-Qi Hua-shi Jie-Du-Fang
NCT04251871	China	Traditional Chinese Medicines
ChiCTR2000029439	China	Traditional Chinese medicine
ChiCTR2000029438	China	Traditional Chinese medicine
ChiCTR2000029589	China	Reduning injection
NCT04310865	China	Yinhu Qingwen Granula
ChiCTR2000029400	China	Traditional Chinese Medicine
ChiCTR2000029763	China	Traditional chinese medicine
ChiCTR2000030219	China	Traditional chinese medicine
ChiCTR2000030188	China	Traditional chinese medicine
ChiCTR2000029434	China	Lian-Hua Qing-Wen Capsule
ChiCTR2000029479	China	Traditional Chinese Medicine
ChiCTR2000029549	China	Traditional Chinese Medicine
ChiCTR2000029558	China	Traditional Chinese Medicine
ChiCTR2000030003	China	Traditional Chinese Medicine
ChiCTR2000029777	China	Traditional Chinese Medicine
ChiCTR2000029869	China	Traditional Chinese Medicine
ChiCTR2000030810	China	Traditional Chinese Medicine
ChiCTR2000029954	China	Honeysuckle oral liquid
ChiCTR2000030545	China	Honeysuckle oral liquid
ChiCTR2000029601	China	Traditional Chinese Medicine
ChiCTR2000030420	China	Traditional Chinese Medicine
NCT04306497	China	Traditional Chinese Medicine
NCT04295551	China	Xiyanping Injection
NCT04275388	China	Xiyanping Injection
ChiCTR2000030388	China	Xue-Bi-Jing injection
ChiCTR2000029941	China	Traditional Chinese Medicine
ChiCTR2000030836	China	Traditional Chinese Medicine
ChiCTR2000030804	China	Exocarpium Citri Grandis
ChiCTR2000029822	China	Honeysuckle decoction
ChiCTR2000030043	China	Shen-Fu injection
ChiCTR2000029756	China	Xiyanping injection
NA	China	Tanreqing Capsules
NA	China	Xiyanping injection
NA	China	Traditional Chinese Medicine
NA	China	Liushenwan

NA	China	Jing-Yin Granule
ChiCTR2000030118	china	Huo-Shen particles
NCT04279197	China	Pulmonary Fibrosis
NA	China	Qing-Wen Bai-Du-Yin
NA	China	Traditional Chinese Medicine
ChiCTR2000030518	China	Zedoary Turmeric Oil
ChiCTR2000030034	China	Traditional Chinese Medicine
NA	China	Jingyebaidu granules
ChiCTR2000029780	China	Shen-Qi Fu-Zheng injection
ChiCTR2000029435	China	Traditional Chinese Medicine
ChiCTR2000029487	China	Gu-Biao Jie-Du-Ling
ChiCTR2000030864	China	Traditional Chinese Medicine
ChiCTR2000029461	China	Traditional Chinese Medicine
ChiCTR2000029493	China	Traditional Chinese Medicine
ChiCTR2000029495	China	Traditional Chinese Medicine
ChiCTR2000029978	China	Dao-Yin
ChiCTR2000029518	China	Traditional Chinese Medicine
ChiCTR2000029578	China	Traditional Chinese Medicine
NCT04323345	Egypt	Natural Honey Treatment
ChiCTR2000030314	China	Traditional Chinese Medicine
ChiCTR2000029755	China	Jingyebaidu granules
ChiCTR2000030704	China	Bufonis Venenum Injection
ChiCTR2000030469	China	Liushenwan
IRCT20200316046792N1 // U07	Iran	herbal syrup and solution
ChiCTR2000030936	China	"Xinguan 2" and "Xinguan 3"
ChiCTR2000029432	China	Tanreqing Injection
ChiCTR2000030255	China	Jing-Yin Granule
ChiCTR2000029976	China	Gymnastic Qigong Yangfeifang
ChiCTR2000030940	China	"Bai-Du Duan Fang"
ChiCTR2000029550	China	Diagnosis and Treatment of Influenza
ChiCTR2000030988	China	Hua-Shi Bai-Du granules
ChiCTR2000030923	China	Traditional Chinese Medicine
ChiCTR2000030166	China	Qing-Wen Bai-Du-Yin
ChiCTR2000031089	China	Tou-Jie-Qu-Wen Granules
ChiCTR2000030117	China	Xiyanping injection
ChiCTR2000031672	China	Traditional Chinese Medicine
ChiCTR2000029430	China	Traditional Chinese Medicine
ChiCTR2000029437	China	Traditional Chinese Medicine
NCT04351542	UK	Ayurveda
ChiCTR2000031203	China	Moxibustion Guidance

ChiCTR2000030386	China	Moxibustion
NCT04374084	China	Moxibustion Plus Cupping

Supplementary data 5 shows the geographical distribution of the 463-treatment based clinical trials against COVID-19 disease.



Supplementary data 6 shows the geographical distribution of the prophylactic clinical trials against SARS-CoV-2 infection.



Supplementary data 7 shows the geographical distribution of the herbal medicine based clinical trials against COVID-19 disease.

